S&P/ASX 200 morning report – 8 ASX shares that reported on Wednesday
Drew Meredith, CFP
August 20, 2020
The S&P/ASX 200 (INDEXASX: XJO) is set to take a
CSL Limited (ASX: CSL) is Australia’s largest (and some might say best) healthcare company, specialising in biopharmaceuticals. Founded in the late 1900s as the Commonwealth Serum Laboratories, CSL was sold by the Australian Government to Australian investors via the share market in 1994 at $2.30 per share, at which time it doubled its size through an international acquisition. CSL is a global leader in blood plasma vaccines (think: the flu) and antivenoms, providing relief for potentially life-threatening medical conditions.
The S&P/ASX 200 (INDEXASX: XJO) is set to take a
CSL Limited (ASX: CSL) shares solidified their position of one
CSL Limited (ASX:CSL) has reported its FY20 report to investors,
ASX blue chips have attracted investors for decades. But are
The S&P/ASX 200 (INDEXASX: XJO) is set to open flat
The S&P/ASX 200 (INDEXASX: XJO) is expected to take a
The Avita Therapeutics Inc (ASX: AVH) share price was trading
What a month it was for the S&P/ASX 200 (INDEXASX:
The S&P/ASX 200 (INDEXASX: XJO) is expected to open lower
Want to level-up your analytical skills and investing insights but don’t know where to start? Join 50,000 Australian investors on our mailing list and we’ll send you our favourite podcasts, courses, resources and investment articles every Sunday morning. Grab a coffee and let Owen and the team bring you the best insights.
Here you go: A $50,000 per year passive income special report
Join more 50,000 Australian investors who read our weekly investing newsletter and we’ll send you our passive income investing report right now.
Simply enter your email address and we’ll send it to you. No tricks. Unsubscribe anytime.
Unsubscribe anytime. Read our Terms, Financial Services Guide, Privacy Policy. We’ll never sell your email address. Our company is Australian owned.